Sutro Biopharma EBIT

The latest EBIT for STRO is $-140M as of June 2026. That compares with $-200M in the prior-year period — up 29.7% year over year. That is below the Healthcare sector average of $23B. Investors often review this figure alongside Sutro Biopharma's historical trend and sector peers before judging valuation or financial health.

Over the past year, STRO's EBIT moved from $-200M to $-140M — a 29.7% year-over-year increase. If the trend continues in the same direction for several quarters, it can signal a meaningful shift in Sutro Biopharma's operating scale or balance-sheet position.

Against Healthcare companies, STRO currently prints $-140M for EBIT, while the sector average sits near $23B. That is roughly 100.6% below the sector mean. Large gaps often invite a closer look at Sutro Biopharma's growth, margins, and balance sheet.

A EBIT figure of $-140M for STRO is a snapshot of scale on that line item. On its own it does not say whether the business is healthy — you also want growth rate, margins, and how the number compares with similar companies. The Healthcare average is about $23B. Explore the charts below for those layers of context.

After noting STRO's EBIT ($-140M), review year-over-year change from $-200M, peer averages, and a few neighboring metrics such as revenue, margins, or valuation multiples. That combination usually beats staring at a single figure. The navigation links on this page jump you to those related views.